Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedJul 8, 2015TPN 3:1, 997 ml with lipids BagsLack of Assurance of Sterility: Sterility of product is not assured.Lincare, Inc. · D-1155-2015Class IITerminatedJul 8, 2015TPN 3:1, 2000 mL BagsLack of Assurance of Sterility: Sterility of product is not assured.Lincare, Inc. · D-1154-2015Class IITerminatedJul 8, 2015TPN 3:1, 2250 mL BagsLack of Assurance of Sterility: Sterility of product is not assured.Lincare, Inc. · D-1153-2015Class IITerminatedJul 8, 2015TPN 3:1, 2400 mL BagLack of Assurance of Sterility: Sterility of product is not assured.Lincare, Inc. · D-1152-2015Class IITerminatedJul 8, 2015OXYCODONE HCl C-II TabletsSuperpotent Drug: Confirmed customer complaint of a single unit dose blister cavity containing 2 OXYCODONE HCl 5 mg tablets.The Harvard Drug Group, LLC · D-1150-2015Class IIITerminatedJul 1, 2015Dr Blue Pain Relieving GelSuperpotent Drug: Product may not be uniformly blended resulting in non-uniform distribution of the active ingredient menthol.Indiana Botanic Gardens, Inc · D-1149-2015Class IIITerminatedJul 1, 2015Lutera (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol tablets USP)Labeling: Incorrect or Missing Package Insert; Product is being recalled because the birth control packs were distributed with out-dated package inserts.Actavis Inc · D-1148-2015Class IIITerminatedJul 1, 2015E-Z-CAT Dry Barium Sulfate for SuspensionFailed stability specifications:This recall has been initiated due to out of specification results for viscosity.Bracco Diagnostic Inc · D-1147-2015Class IIITerminatedJun 24, 2015Amlodipine besylate and Atorvastatin calcium tabletsSubpotent drugDr. Reddy's Laboratories, Inc. · D-1146-2015Class IIITerminatedJun 24, 2015Amlodipine besylate and Atorvastatin calcium tabletsSubpotent drugDr. Reddy's Laboratories, Inc. · D-1145-2015Class IIITerminatedJun 24, 2015Amlodipine besylate and Atorvastatin calcium tabletsSubpotent drugDr. Reddy's Laboratories, Inc. · D-1144-2015Class IIITerminatedJun 24, 2015Amlodipine besylate and Atorvastatin calcium tabletsSubpotent drugDr. Reddy's Laboratories, Inc. · D-1143-2015Class IIITerminatedJun 24, 2015Loratadine Orally Disintegrating Tablets USPSuperpotent Drug: Out Of Specification (OOS) result for Assay.Ohm Laboratories, Inc. · D-1142-2015Class IITerminatedJun 24, 2015NEXIUM¿Presence of Foreign Tablets/Capsules: Confimed customer compliant by a retail pharmacist that an unopened bottle labeled as NEXIUM¿ capsules contained 60 SEROQUEL¿ XR...AstraZeneca Pharmaceuticals LP · D-1141-2015Class IITerminatedJun 24, 2015Lamivudine and Zidovudine Tablets USP 150mg/300mg 30 Unit Dose BlistersFailed dissolution specificationsAmerican Health Packaging · D-1140-2015Class IIITerminatedJun 24, 2015Fentanyl Citrate InjFailed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548).West-Ward Pharmaceutical Corp. · D-1139-2015Class IIITerminatedJun 24, 2015Foradil AerolizerFailed Stability Specification: out of specification result obtained for the Particle Size Distribution test during stability testing.Novartis Pharmaceuticals Corp. · D-1138-2015Class IIITerminatedJun 24, 2015Foradil AerolizerFailed Stability Specification: out of specification result obtained for the Particle Size Distribution test during stability testing.Novartis Pharmaceuticals Corp. · D-1137-2015Class IITerminatedJun 24, 2015Divalproex Sodium Extended-Release TabletsFailed Dissolution Specifications; exceeded specification at the 9 hour time pointDr. Reddy's Laboratories, Inc. · D-1136-2015Class IITerminatedJun 24, 2015Divalproex Sodium Extended-Release TabletsFailed Dissolution Specifications; exceeded specification at the 9 hour time pointDr. Reddy's Laboratories, Inc. · D-1135-2015Class IITerminatedJun 24, 2015Famotidine TabletsCGMP Deviations: Failure of the manufacturer, Wockhardt Ltd, to adequately investigate customer complaints.Allegiant Health · D-1134-2015Class IITerminatedJun 17, 2015PHENYLephrine HCl 50 mg in 0.9% Sodium Chloride 250 mL bagLabeling: Label Mix-Up: Product is incorrectly labeled as phenylephrine 50 mg in 0.9% sodium chloride rather than phenylephrine 50 mg in 5% dextrose.SCA Pharmaceuticals · D-1133-2015Class IITerminatedJun 17, 2015MD-GastroviewLabeling: incorrect or missing lot number and/or expiration dateMallinckrodt, Inc. · D-1132-2015Class IITerminatedJun 17, 2015Heparin Sodium and 0.9% Sodium Chloride InjectionSubpotent Drug; out of specification results for heparin raw materialBaxter Healthcare Corp · D-1131-2015Class IITerminatedJun 17, 2015Hydroxyzine HydrochlorideFailed Impurities/Degradation SpecificationsAkorn, Inc. · D-1130-2015Class IITerminatedJun 17, 2015Hydroxyzine HydrochlorideFailed Impurities/Degradation SpecificationsAkorn, Inc. · D-1129-2015Class IITerminatedJun 17, 2015AlprostadilLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1128-2015Class IITerminatedJun 17, 2015Trimix (PGE1Lack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1127-2015Class IITerminatedJun 17, 2015Trimix (PGE1Lack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1126-2015Class IITerminatedJun 17, 2015Trimix (ALack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1125-2015Class IITerminatedJun 17, 2015Trimix (ALack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1124-2015Class IITerminatedJun 17, 2015HyaluronidaseLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1123-2015Class IITerminatedJun 17, 2015Glutathione INHALATIONLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1122-2015Class IITerminatedJun 17, 2015Glutathione INHALATIONLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1121-2015Class IITerminatedJun 17, 2015Bimix (PHENTLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1120-2015Class IITerminatedJun 17, 2015Avastin, solutionLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1119-2015Class IITerminatedJun 17, 2015AlprostadilLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1118-2015Class IITerminatedJun 17, 2015AlprostadilLack of Assurance of Sterility; objectionable conditions observed during a FDA inspectionMontana Compounding Pharmacy · D-1117-2015Class IITerminatedJun 17, 2015Nifedipine Extended-Release TabletsFailed Dissolution Specifications: High out of specification dissolution result at 1 hour time point.Valeant Pharmaceuticals North America LLC · D-1116-2015Class IIITerminatedJun 10, 2015Cetirizine HCl Chewable TabletFailed Impurities/Degradation Specifications: An out of specification (OOS) result was reported for impurity at the 21 month stability time point.Sandoz, Inc · D-1115-2015

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.